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Implantation of the Melody Transcatheter
Pulmonary Valve in Patients With a Dysfunctional
Right Ventricular Outflow Tract Conduit
Early Results From the U.S. Clinical Trial
Evan M. Zahn, MD,* William E. Hellenbrand, MD,† James E. Lock, MD,‡
Doff B. McElhinney, MD‡
Miami, Florida; New York, New York; and Boston, Massachusetts
Objectives This study was designed to evaluate the safety, procedural success, and short-term effectiveness of the Melody
transcatheter pulmonary valve (Medtronic, Inc., Minneapolis, Minnesota) in patients with dysfunctional right ven-
tricular outflow tract conduits.
Background Conduit dysfunction has recently been treated with transcatheter pulmonary valve placement. There have been
no prospective, multicenter trials evaluating this technology.
Methods Standardized entry criteria, implantation, and follow-up protocols were used. Nonimplanting core laboratories
were used to evaluate results.
Results Between January 2007 and September 2007, 34 patients underwent catheterization for intended Melody valve
implantation at 3 centers. Mean age was 19.4  7.7 years. Initial conduit Doppler mean gradient was 28.8 
10.1 mm Hg, and 94% of patients had moderate or severe pulmonary regurgitation (PR). Implantation was suc-
cessful in 29 of 30 attempts and not attempted in 4 patients. Procedural complications included conduit rupture
requiring urgent surgery and device removal (n  1), wide-complex tachycardia (n  1), and distal pulmonary
artery guidewire perforation (n  1). Peak systolic conduit gradient fell acutely from 37.2  16.3 mm Hg to
17.3  7.3 mm Hg, and no patient had more than mild PR. There were no deaths or further device explants. At
6-month follow-up, conduit Doppler mean gradient was 22.4  8.1 mm Hg, and PR fraction by magnetic reso-
nance imaging was significantly improved (3.3  3.6% vs. 27.6  13.3%, p  0.0001). Stent fracture occurred
in 8 of 29 implants; 3 of these were treated with a second Melody valve for recurrent stenosis later in follow-up.
Conclusions Implantation of the Melody valve for right ventricular outflow tract conduit dysfunction can be performed by ex-
perienced operators at multiple centers, appears safe, and has encouraging acute and short-term outcomes.
(J Am Coll Cardiol 2009;54:1722–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.034t
f
a
t
e
b
i
w
m
l
d
d
c
T
bince being described more than 40 years ago, the use of
ight ventricle (RV)-to-pulmonary artery (PA) conduits has
acilitated repair of numerous congenital heart defects.
he life span of right ventricular outflow tract (RVOT)
onduits is limited, however, and patients may undergo
ultiple re-interventions over the course of a lifetime to
reat conduit dysfunction (1–3). Modes of conduit dysfunc-
ion include stenosis and regurgitation, often in combina-
rom the *Division of Cardiology, Miami Children’s Hospital, Miami, Florida;
Division of Cardiology, Morgan Stanley Children’s Hospital, New York, New York;
nd the ‡Department of Cardiology, Children’s Hospital Boston, Boston,
assachusetts. Drs. Zahn, Hellenbrand, and McElhinney all act in consultant and/or
nvestigator roles for Medtronic, Inc., the manufacturer of the Melody valve. Dr. Lock
eceives royalties on products sold by Cook and NMT, unrelated to this article.a
Manuscript received March 17, 2009; revised manuscript received June 16, 2009,
ccepted June 22, 2009.ion. Although surgical conduit replacement can be per-
ormed with low mortality, these operations may be
ssociated with significant morbidity and are often pallia-
ive, with newly placed conduit valves often displaying
vidence of dysfunction within a year (4). Placement of
are-metal stents has been shown to postpone surgery, but
s only useful to treat conduit stenosis and frequently
orsens pulmonary regurgitation (PR), as the most com-
on area of stenosis typically involves the conduit valve
eaflets (5,6). Mounting evidence suggests that PR can have
eleterious effects, including progressive RV dilation and
ysfunction, diminished exercise tolerance, and an in-
reased risk of arrhythmias and sudden death (7,8).
imely restoration of pulmonary valve function may
enefit patients with PR (9,10). In 2000, Bonhoeffer et
l. (11) reported the first successful transcatheter pulmo-
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October 27, 2009:1722–9 Early Results From the Transcatheter Pulmonary Valve Trialary valve implantation, and the successor to that valve,
he Melody transcatheter pulmonary valve (Medtronic,
nc., Minneapolis, Minnesota), has been available in
urope and Canada for several years. This study de-
cribes short-term results of the U.S. Melody feasibility study,
he first prospective multicenter trial of this valve with stan-
ardized entry criteria, implantation protocol, and follow-up
valuation.
ethods
tudy design. This was a prospective, nonrandomized
tudy designed to assess the safety, procedural success, and
hort-term effectiveness of the Melody valve in patients with
ysfunctional RVOT conduits. Patient selection was based
n specific inclusion and exclusion criteria (Table 1). Pa-
ients were categorized as having a primary implant indica-
ion of stenosis, PR, or mixed stenosis and PR. Pre-
mplantation and follow-up studies were performed at
re-determined intervals (Table 2), and results of cardiac
agnetic resonance imaging (cMRI), echocardiography,
ardiopulmonary exercise testing (CPET), and computed
omography (CT) pulmonary angiography were interpreted
y independent core laboratories. Each case was reviewed
nd approved by an independent pediatric cardiologist and
ardiac surgeon before enrollment.
utcome measures. Primary outcome measures were de-
ned for safety, procedural success, and short-term effec-
iveness (Table 3).
chocardiography. Conduit mean gradients were deter-
ined by tracing the border of continuous-wave spectral
oppler recordings and integrating the area under the
urve. PR was assessed using color and pulse wave Doppler
nterrogation in the RVOT proximal to the conduit, main
A, and proximal branch PAs and was categorized as none,
race, mild, moderate, or severe, based on regurgitant jet
nclusion/Exclusion Criteria for Study EntryTable 1 Inclusion/Exclusion Criteria for Study Entry
Inclusion Criteria Exclusion Criteria
Age 5 yrs Active endocarditis
Weight 30 kg Major progressive noncardiac disease
Original conduit diameter 16 mm
Echocardiographic RVOT conduit
dysfunction
Patients classified as NYHA functional
class II, III, IV: Doppler mean
gradient 35 mm Hg or
 moderate PR*
Patients classified as NYHA I: Doppler
mean gradient 40 mm Hg or
severe PR† associated with TV
annulus z-score 2 or RVFS 40%
Central vein occlusion or significant
obstruction
Pregnancy
Intravenous drug abuse
Contraindication to MRI
Unable/unwilling to sign informed
consent or comply with follow-up
Moderate PR  regurgitant color Doppler jet width 20% to 40% of the valve annulus or diastolic
ow reversal extending into the distal main pulmonary artery. †Severe PR  regurgitant color
oppler jet width 40% of the valve annulus or diastolic flow reversal extending into proximal
ranch pulmonary arteries.
NYHA  New York Heart Association; MRI  magnetic resonance imaging; PR  pulmonarym
egurgitation; RVFS  right ventricle fractional shortening; RVOT  right ventricular outflow tract;
V  tricuspid valve.idth relative to conduit width
nd the extent of PA diastolic
ow reversal (Table 1).
MRI. Short-axis cine images
ere obtained using a steady-
tate free precession technique,
overing both ventricles from the
pex to the base. Flow measure-
ents were obtained by selecting
plane through the main PA and
erforming a breath-through,
elocity-encoded, phase-contrast
cquisition. Ventricular mass and
olumes were calculated by man-
ally tracing the epicardial and
ndocardial contours, without
eparate exclusion of trabeculae
ot continuous with the mural
urface on each slice.
PET. CPET was performed using bicycle ergometry
ith a ramp protocol. Peak oxygen consumption (VO2) at
naerobic threshold was measured by the V-slope method
nd cross-checked with the ventilatory equivalent method.
T pulmonary angiography. CT pulmonary angiography
as performed using 16, 32, or 64 detector-row scanners
nd thin-section images obtained using an intravenous
olus of contrast, with image acquisition timed from opaci-
cation of the main PA. Distal PA vasculature was exam-
ned for findings of acute or chronic thromboembolism.
ardiac catheterization protocol. Patients who met entry
riteria underwent cardiac catheterization using general
ndotracheal anesthesia. The peak-to-peak RV-PA gradi-
nt was calculated as the difference in systolic pressure
etween RV body and main PA distal to the conduit. If
tenosis was the primary indication and the RV/aorta
ystolic pressure ratio was 0.66, the patient was excluded
nd implantation not attempted. Angiography was per-
ormed in the RV, conduit, and aortic root. If there was
uspicion that a coronary artery was at risk for compression
rom valve implantation, coronary angiography was per-
ormed with an angioplasty balloon simultaneously inflated
n the conduit. Patients with coronary compression were
xcluded from implantation. Conduit pre-dilation was per-
ormed in all patients using a balloon 2 mm larger than
he narrowest diameter of the conduit and 110% the
riginal conduit diameter. If the balloon waist measured
etween 14 and 20 mm on subsequent low-pressure (8
tm) balloon sizing, Melody valve implantation was at-
empted; otherwise, the conduit was considered anatomi-
ally unsuitable, and no implantation was attempted. After
elody valve implantation, hemodynamics and PA angiog-
aphy were repeated. Post-dilation of the valve was per-
itted at the discretion of the operator. Additional in-
erventional procedures during the same catheterization
rocedure, including stenting of the conduit with a bare-
Abbreviations
and Acronyms
cMRI  cardiac magnetic
resonance imaging
CPET  cardiopulmonary
exercise test/testing
CT  computed
tomography
NYHA  New York Heart
Association
PA  pulmonary artery
PR  pulmonary
regurgitation
RV  right ventricle
RVOT  right ventricular
outflow tract
VO2  oxygen consumptionetal stent, were not permitted. All patients received
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ntibiotic prophylaxis during and after the procedure.
hest radiography. Standard posteroanterior and lateral
hest radiography was performed before discharge and at all
ollow-up visits except 6 months. At the 6-month visit,
inefluoroscopy was performed to enhance the ascertain-
ent of stent fracture, using multiple projections to opti-
ize visualization and dynamic imaging to evaluate the
ossibility of variable strut separation across the cardiac
ycle with minor fractures.
elody valve and Ensemble (Medtronic, Inc.) delivery
ystem. The device and delivery system and their use have
een described previously (11,12).
ata Safety Monitoring Board. A Data Safety Monitor-
ng Board consisting of a biostatistician, a cardiothoracic
urgeon, and an interventional cardiologist assessed interim
afety.
tatistical analysis. The subset evaluated for safety in-
luded all patients who underwent catheterization. The
ubset evaluated for procedural success included only pa-
ients in whom implantation was attempted. The subset
valuated for short-term effectiveness included patients in
hom a Melody valve was implanted and was not explanted
Schedule of Follow-Up TestingTable 2 Schedule of Follow-Up Testing
Evaluation/Visit Pre-Implantation Discharg
Clinical assessment X X
Echocardiogram X X
Chest X-ray X
Fluoroscopy
Urinalysis X
ECG X
cMRI X
CPET X
CTA X
cMRI  cardiac magnetic resonance imaging; CPET  cardiopulmon
ECG  electrocardiogram.
rimary Outcome MeasuresTable 3 Primary Outcome Measures
Safety
Percentage of patients with procedure- or device-related mortality during
6 months of follow-up
Percentage of patients with procedure- or device-related AEs during 6 months
of follow-up
Procedural success
Percentage of patients with successful valve implantation, defined as:
● Valve fixed within desired location
● RV-PA peak gradient measured by catheter 35 mm Hg
● Trivial or less pulmonary regurgitation*
● Freedom from valve explant 24 h after implantation
Short-term effectiveness
Percentage of patients with acceptable valve function at 6 months, defined as:
● Pulmonary regurgitant fraction 20%†
● RVOT Doppler mean gradient 30 mm Hg
Measured by angiography, †Measured by cardiac magnetic resonance imaging.t
AE  adverse event; PA  pulmonary artery; RV  right ventricle; RVOT  right ventricular
utflow tract.uring the first 24 h. Statistical analyses were performed
sing SAS (SAS Institute Inc., Cary, North Carolina)
ersion 9.1 software. The Wilcoxon signed-rank test was
sed to evaluate the change in continuous paired data
before implantation to 6 months). The Hochberg proce-
ure was implemented to account for multiplicity (13,14).
djusted p values are presented in the text and tables. An
djusted p value 0.05 was considered statistically signifi-
ant. The study was approved by the Institutional Review
oard at each institution, and written informed consent was
btained from each patient or his/her parents before the
aseline echocardiogram.
esults
atients. The study population consisted of 34 patients
ho underwent catheterization after meeting inclusion cri-
eria. On the basis of echocardiographic entry criteria, the
rimary indication for study entry was PR in 23 patients,
onduit stenosis in 6 patients, and mixed PR and conduit
tenosis in 5 patients, although most patients with a primary
ndication of stenosis had some degree of PR, and patients
ith a primary indication of PR had some stenosis. Baseline
haracteristics are provided in Table 4. The majority of
atients were symptomatic (82% with New York Heart
ssociation [NYHA] functional class II or III). Nearly all
94%) had had moderate or severe PR, and 35% had
oderate or severe tricuspid regurgitation.
rocedural success. Melody valve implantation was at-
empted in 30 of 34 patients who underwent catheteriza-
ion. Implantation was not attempted in 4 patients due to
isk of coronary compression (n  2), need for concomitant
ulmonary artery stenting (disallowed by protocol) (n  1),
nd an RV/aorta pressure ratio 0.66 in a patient with
tenosis as the primary indication (n  1). Average proce-
ure time was 182.0  84.4 min, and average hospitaliza-
ion was 1.3  1.2 days. Three patients experienced
rocedural adverse events: conduit rupture treated with
mergent surgery (n 1), wide-complex tachycardia treated
ith cardioversion (n  1), and a distal pulmonary artery
ranch perforation secondary to a guidewire treated with
1 Month 3 Months 6 Months Annual
X X X X
X X X X
X X X
X
X X
X
X
X X
X
rcise testing; CTA  computed tomography pulmonary angiography;eranscatheter vascular occlusion (n  1). All 3 patients were
d
w
a
p
i
g
t
t
p

S
f
t
h
a
v
A
R
p
p
(
P
C
a
w
t
p
E
d
P
a
w
D
H
m
g
t
s
a
t
p
h
b
p
N
c
b
c
w
C
D
*
1725JACC Vol. 54, No. 18, 2009 Zahn et al.
October 27, 2009:1722–9 Early Results From the Transcatheter Pulmonary Valve Trialischarged within 7 days. Criteria for procedural success
ere met in 93% (28 of 30) of attempted implantations. In
ddition to the patient with conduit rupture, the other
atient categorized as a procedural failure had a post-
mplantation RV-PA peak gradient of 37 mm Hg. The
linical Characteristics of Study Patients (n  34)Table 4 Clinical Characteristics of Study Patients (n  34)
Variable/Category
Weight, kg 61.1 15.3
Sex
Male 26 (77)
Female 8 (23)
Age, yrs 19.4 7.7
Original diagnosis
Tetralogy of Fallot 18 (52)
Truncus arteriosus 4 (12)
Aortic valve disease (Ross procedure) 4 (12)
Transposition of the great arteries 3 (9)
Other 5 (15)
NYHA functional classification
I 6 (18)
II 23 (67)
III 5 (15)
IV 0 (0)
RVOT conduit type
Homograft 27 (79)
Biologic valved conduit 3 (9)
Other* 4 (12)
RVOT conduit size 20.0 2.1
Primary indication for implantation
Stenosis 6 (18)
Regurgitation 23 (67)
Mixed stenosis and regurgitation 5 (15)
Pre-existing stents in RVOT conduit
No pre-existing stents in RVOT conduit 19 (56)
Single stent in RVOT conduit 12 (35)
Multiple stents in RVOT conduit 3 (9)
Number of previous open surgeries 2.2 1.0
PR by echocardiography
None 0 (0)
Trace 0 (0)
Mild 1 (3)
Moderate 12 (35)
Severe 20 (59)
Unable to assess 1 (3)
Average conduit Doppler mean gradient (mm Hg) 28.4 11.4
ata are presented as mean  SD for continuous data or n (%) of subjects for categorical data.
Other conduit types were nonvalved “tube grafts,” nonvalved homograft, and bioprosthesis.
Abbreviations as in Table 1.
Acute Hemodynamic Catheterization Data (n Table 5 Acute Hemodynamic Catheterizatio
Variable Pre-Implanta
RV systolic pressure, mm Hg 67.7 16.1 (68;
RV/aortic systolic pressure ratio 0.7 0.2 (0.7;
RV-PA gradient, mm Hg 37.2 16.3 (39;
PA diastolic pressure, mm Hg 11.0 5.2 (10; 1Data are presented as mean  SD (median; minimum–maximum).
Abbreviations as in Table 3.radient across the Melody valve was only 5 mm Hg, but
here was subvalvar muscular obstruction, which resulted in
he elevated RV-PA gradient. In subsequent follow-up, this
atient’s conduit Doppler mean gradient was consistently
25 mm Hg, and no further intervention was performed.
hort-term effectiveness. In terms of the short-term ef-
ectiveness criteria defined in Table 3, 29 patients retained
he Melody valve at 24 h, and 24 (83%) had acceptable
emodynamics at the 6-month time point. Follow-up data
re presented for the 29 patients who retained a Melody
alve at 24 h.
CUTE HEMODYNAMIC RESULTS. After valve implantation,
V systolic pressure, RV-PA gradient, and the RV/aortic
ressure ratio were significantly lower, and the PA diastolic
ressure was significantly higher than before implantation
Table 5). Pre-discharge echocardiography demonstrated no
R or trivial PR in 86% of patients and mild PR in 14%.
LINICAL ASSESSMENT. NYHA functional class improved
fter Melody valve implantation (Fig. 1). Of 24 patients
ho were NYHA functional class II or III before implan-
ation, 19 (79%) had an improvement of at least 1 class; no
atient experienced a decline in NYHA functional class.
CHOCARDIOGRAPHY. Valve competence was maintained
uring follow-up, with 93% of patients having no/trivial
R and no patient having more than mild PR 6 months
fter implantation. Improvement of conduit obstruction
as maintained for the group as a whole, with average
oppler mean gradient improving from 28.8  10 mm
g before implantation to 22.4  8.1 mm Hg at 6
onths (p  0.001). Five patients had Doppler mean
radients 30 mm Hg at 6-month follow-up. One of
hese patients had a major stent fracture and underwent a
uccessful second Melody valve implantation, 1 had
symmetric expansion of the Melody valve and was
reated successfully using high-pressure balloon angio-
lasty, 1 was discovered at subsequent catheterization to
ave obstruction below the conduit, 1 had stent fracture
ut had not undergone repeat catheterization, and in 1
atient there was no obvious explanation. All 5 were in
YHA functional class I at most recent follow-up.
MRI. Twenty-five patients (83%) had paired cMRI data
efore and 6 months after implantation (Table 6). Signifi-
ant reductions in PR fraction and RV end-diastolic volume
ere seen. The median PR fraction was 3.1% at 6 months
a (n  29)
Post-Implantation p Value
8) 48.9 13.7 (46; 26–82) 0.001
0) 0.4 0.1 (0.4; 0.3–0.75) 0.001
17.3 7.3 (18; 5–37) 0.001
14.7 5.1 (15; 4–28) 0.00129)n Dat
tion
32–10
0.3–1.
9–69)
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Early Results From the Transcatheter Pulmonary Valve Trial October 27, 2009:1722–9nd was no higher than 11.6% in any patient. No significant
hanges were noted in RV or left ventricular ejection
raction or left ventricular end-diastolic volume.
PET. Twenty-nine patients had paired CPET data from
efore and 6 months after implantation. There were no
ifferences between pre-implantation and 6-month follow-up
eak VO2 (21.6 6.8 ml/kg/min vs. 22.7 7.1 ml/kg/min,
 1.0) or anaerobic threshold (15.0  4.7 ml/kg/min vs.
5.5  5.6 ml/kg/min, p  1.0).
T PULMONARY ANGIOGRAPHY. Twenty-nine patients had
aired CT pulmonary angiography before and 6 months
fter implantation, and no new findings of pulmonary
mboli were discovered. One patient had findings of chronic
ulmonary emboli in the right upper lobe noted on the
re-implantation CT, which remained unchanged at
-month follow-up.
ADIOGRAPHY/CINEFLUOROSCOPY. Stent fractures were
bserved in 8 of 29 patients (28%) during follow-up, 1 at 3
onths and the others at 6 months. When diagnosed, all 8
Figure 1 New York Heart Association Functional Classification
of Time for Patients Receiving a Melody Valve (Medtr
Cardiac Magnetic Resonance Imaging Results B6 Months After Melody Valv (Medtronic, Inc.)Table 6 Cardiac Magnetic R so a Imag6 Months After Melody Valve (Med
Variable Pre-Implantation
PR fraction, % 27.6 13.3 (29.8; 4.3–61.
RV EDV index, ml/m2 144.7 54.8 (133.5; 72.5–2
RV ejection fraction, % 40.8 14.6 (39.8; 10.5–72
LV EDV index, ml/m2 84.5 18.9 (85.7; 43.9–12
LV ejection fraction, % 52.6 10.5 (54.3; 31.3–68Data are presented as mean  SD (median; minimum–maximum).
EDV  end-diastolic volume; LV  left ventricle; PR  pulmonary regurgitaatients were NYHA functional class I, and all but 1 had
ess than trace PR and a conduit Doppler mean gradient
30 mm Hg. Although most of these fractures were minor
i.e., a single wire break with no loss of stent integrity), 3
atients had a second Melody valve implanted 11, 12, and
4 months after the initial implantation to treat progressive
onduit obstruction associated with multiple fracture points,
oss of stent integrity, and progression to NYHA functional
lass II. Implantation of a second Melody valve was uncom-
licated and preceded by placement of bare-metal stainless
teel stents in all 3 cases. Hemodynamic results after repeat
elody valve implantation were similar to initial implanta-
ion. The other 5 patients with minor stent fractures
emained stable in NYHA functional class I without evi-
ence of a loss of stent integrity or progressive RVOT
bstruction. Freedom from re-intervention for stent fracture
ssociated with recurrent RVOT obstruction was 96.6% at 1
ear (Fig. 2).
afety. Aside from the procedural adverse events, stent
ractures, and re-interventions summarized above, no other
Function
Inc.) (n  29)
andntation (n  25)sults Before and
, Inc.) Implantation (n  25)
Post-Implantation p Value
3.3 3.6 (3.1; 0.0 - 11.6) 0.001
117.3 48.3 (109.5; 54.3–256.1) 0.001
42.0 12.1 (39.8; 23.8–63.8) 0.86
90.7 20.4 (90.8; 58.5–132.9) 0.30
52.4 8.6 (52.1; 33.3–68.5) 1.0as aeforeImplaing R
tronic
0)
90.8)
.7)
1.4)
.8)tion; RV  right ventricle.
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October 27, 2009:1722–9 Early Results From the Transcatheter Pulmonary Valve Trialdverse events were reported. With respect to the safety
utcome criteria, 100% of patients were free from
rocedure- or device-related death, and 91% were free from
erious procedure- or device-related events.
iscussion
o date, the only published series of Melody valve
mplantation have been from the Bonhoeffer group and
emonstrate excellent short- and intermediate-term results
11,12). This study confirms that equally good acute and
hort-term results can be achieved by trained, experienced
perators at multiple other centers. Furthermore, it is the
rst prospective multicenter clinical trial of the Melody
alve that uses defined entry criteria, standardized implan-
ation and follow-up protocols, independent core laborato-
ies for assessment of outcomes, and cinefluoroscopy and
T pulmonary angiography to evaluate for stent fracture
nd pulmonary embolism.
rocedural success and short-term effectiveness. The
rocedural success rate in this series was high (29 of 30
ttempts) and compared favorably with results published by
xperienced operators (12,15). The current system design
akes Melody valve implantation simple and comparable
echnically to bare-metal stent implantation, a common
ntervention performed in most congenital catheterization
aboratories. There were no device malpositions or emboli-
ations in this series. The current delivery system, designed
pecifically for this application, protects the stent and
reserves the balloon–stent relationship during advance-
ent to the RVOT and may offer some advantages over
onventional methods of stent implantation. The average
Figure 2
Kaplan-Meier Curve Depicting
Freedom From Re-Intervention for
Stent Fracture and Associated RVOT Obstruction
Error bars shown are at the 95%
confidence intervals. RVOT  right ventricular outflow tract.ospital stay of just over 1 day in this study compares aavorably with both surgical conduit replacement and bare-
etal stenting.
In the current study, a minimum sizing balloon waist
f 14 mm was required to undergo valve implantation.
sing this approach, only 1 patient had a post-
mplantation RV-PA gradient that was considered inad-
quate by pre-determined criteria. Pre-dilation of the
onduit before sizing was a required component of the
rotocol for conduits with an angiographic diameter 18
m, but pre-stenting was not allowed in this initial
ohort (the protocol has since been modified to allow
oncomitant procedures, including pre-stenting of the con-
uit). The rationale for pre-dilation was to optimize conduit
iameter before balloon sizing and Melody valve implantation
nd to assess compliance of the conduit and identify multiple
r highly resistant stenoses. As Sugiyama et al. (16) confirmed
n their series of bare-metal stenting for conduit obstruction,
he smaller the achieved diameter of the conduit relative to the
ormal pulmonary valve size for the patient, the higher the
ost-intervention RVOT gradient. This may be more im-
ortant with an implantable valve, in which the valve and
ein segment add bulk to the implant site and may contrib-
te to luminal narrowing and obstruction if the stent is
nder-expanded.
In the patient with a post-implantation peak RVOT
radient of 37 mm Hg, the obstruction was below the
onduit and unrelated to the Melody valve itself. Four other
atients developed Doppler mean gradients30 mm Hg by
-month follow-up. These outcomes highlight the impor-
ance of appropriate patient selection for the Melody valve.
s more data become available, it will be important to
valuate patient-related and procedural data associated with
arly recurrence of conduit obstruction to improve patient
election and execution of the procedure. It will also be
mportant to determine the role of pre-dilation and/or
re-stenting in preventing recurrent RVOT obstruction.
Consistent with prior reports, function of the Melody
alve was excellent in short-term follow-up, with no or
rivial PR in almost all patients, and none with more than
ild regurgitation (11,12,15). RVOT gradients were sig-
ificantly lower at 6 months than before implantation, and
RI demonstrated favorable RV volume remodeling. A
ajority of patients improved in NYHA functional class,
nd none declined, consistent with prior reports (12).
lthough symptomatic improvement was typically noted 1
onth after implantation, some patients continued to im-
rove as late as 6 months after implantation, raising the
ossibility that cardiac remodeling and conditioning may
ontinue beyond the acute restoration of pulmonary valve
ompetence (21). In the current series, we did not observe
ignificant improvements in maximal VO2 and anaerobic
hreshold, although the preponderance of patients with PR
s the primary indication for valve placement may be a
actor in this finding. Coats et al. (22) reported that patients
ith PR have minimal improvement in maximal VO2 andnaerobic threshold after Melody valve implantation, in
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tenosis (22). Further examination of the physiologic mech-
nisms underlying changes in exercise performance and
ymptomatic improvement is warranted.
tent fracture. Stent fracture, well described after both
are-metal stenting of RVOT conduits and Melody valve
mplantation, was an important finding in this study
19,23). Peng et al. (19) described 221 patients treated for
onduit obstruction with bare-metal stenting and found a
3% incidence of stent fracture, with external compression
nd a substernal conduit location identified as important
isk factors. In a series of 123 patients who underwent
elody valve placement, Nordmeyer et al. (23) reported a
5% freedom from Melody stent fracture at 2 years, with
mplantation in the native RVOT, no calcification along the
VOT, and greater recoil after balloon deflation associated
ith a higher risk of fracture. It is logical to postulate from
hese 2 studies that when excessive external loading forces
re applied to stents in the RVOT, either from dynamic
ompression or other cyclic stresses, there is an important
isk of stent fracture. The current series includes too few
atients to provide robust insight into this issue, but the
requency of stent fracture appears consistent with these
arlier reports. Nordmeyer et al. (24) recently reported a
eries of patients who underwent successful treatment of
e-stenosis after Melody stent fracture, with bare-metal
tenting followed by implantation of a second Melody valve.
he same approach was used in 3 patients in this series,
ith good acute results. Further attention is needed to
etter understand the risk factors for, prevention of, and
reatment of stent fracture in patients undergoing transcath-
ter pulmonary valve placement.
afety. The procedural adverse event rate of 9% in this
ohort is acceptable for a new procedure of this magnitude
nd compares favorably with previously published reports
nvolving catheter or surgical intervention for conduit dys-
unction (1–3,16–20). The large profile of the delivery
ystem did not result in any obvious vascular damage or
rohibit delivery of the device in any patient, including
hildren as young as 10 years. Importantly, none of the
dverse events in this study resulted in death or long-term
equelae. Aside from stent fractures and re-interventions, as
iscussed above, there were no device- or procedure-related
dverse events reported during follow-up.
rotocol. There are challenges to developing a standard-
zed, rigorous protocol for percutaneous pulmonary valve
lacement in individuals with dysfunctional RVOT con-
uits and a spectrum of hemodynamic disease that includes
ariable degrees of PR and obstruction. There are limited
ata from which to define rigorous, outcome-based indica-
ions for valve implantation. Moreover, the indications for
mplantation and metrics of success will necessarily differ for
atients at different points on this disease spectrum, and
here is no simple means of capturing the complexities of
ixed disease. The inclusion criteria for this protocol wereesigned to reflect general practice on the basis of theublished literature and the experience of the participating
enters and were graduated according to symptomatic sta-
us. To address the question of clinical equipoise, 2 inde-
endent physicians, 1 congenital cardiac surgeon and 1
ediatric cardiologist, reviewed prospective patients and
rovided written support for the decision to implant a
elody valve. Nevertheless, individuals varied within the
ohort, and our population may have differed in composi-
ion from that of previously reported series (12,21). Echo-
ardiographic assessment of hemodynamic entry criteria
ay be considered a limitation of the study protocol and was
hosen for logistical reasons. The catheterization protocol
sed in this study was successful in identifying 2 patients at
isk for coronary compression, a potentially fatal complica-
ion. Pre-implantation balloon inflation with simultaneous
oronary angiography should be used in any case of conduit
tenting or transcatheter valve implantation when coronary
rtery compression is suspected. Further, the protocol spec-
fied cinefluoroscopy at the 6-month follow-up visit to
ssess for stent fracture. The decision to use cinefluoroscopy
as based on its anticipated high sensitivity for detecting
ven minor stent fractures.
onclusions
his is the first multicenter prospective trial of an implant-
ble transcatheter pulmonary valve in a population of
atients with congenital heart disease and RVOT conduit
ysfunction. The implantation success rate was high, the
requency of adverse events was acceptable, and short-term
utcomes were encouraging, supporting the conclusion that
his technology can be translated effectively to experienced,
roperly trained interventional cardiologists and is not
ighly operator dependent. Longer follow-up and a larger
atient experience are needed to determine the ultimate role
f this therapy in the treatment of conduit dysfunction.
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